Schistosomiasis therapeutics: whats in the pipeline?

References

• Liu R, Dong HF, Guo Y, et al. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011;4:201.
   PubMed Web of Science ®Google Scholar
• Utzinger J, Xiao S, Keiser J, et al. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem. 2001;8:1841–1860.
   PubMed Web of Science ®Google Scholar
• Valentim CL, Cioli D, Chevalier FD, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science. 2013;342:1385–1389.
   PubMed Web of Science ®Google Scholar
• UNICEF water, sanitation and hygiene strategies for 2006-2015 [cited 2015 Jul 14]. Available from: http://www.unicef.org/about/execboard/files/06-6_WASH_final_ODS.pdf.
   Google Scholar
• Duffin J, René P. “Anti–moine; Anti–biotique”: The public fortunes of the secret properties of Antimony Potassium Tartrate (Tartar Emetic). J History Med Allied Scie. 1991;46:440–456.
   PubMed Web of Science ®Google Scholar
• Khayyal MT. The effects of antimony uptake on the location and pairing of Schistosoma mansoni. British J Pharmacol Chemoth. 1964;22:342–348.
   PubMed Web of Science ®Google Scholar
• Davis A, Bailey DR. Metrifonate in urinary schistosomiasis. Bull World Health Organization. 1969;41:209–224.
   PubMed Web of Science ®Google Scholar
• Kramer CV, Zhang F, Sinclair D, et al. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2014;8:CD000053.
   PubMedGoogle Scholar
• Doenhring E, Poggensee U, Feldmeier H. The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans. Am J Trop Med Hyg. 1986;35(2):323–329.
   PubMed Web of Science ®Google Scholar
• Danso-Appiah A, Utzinger J, Liu J, et al. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;3:CD000053.
   Google Scholar
• Schneider LS. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease. Dialogues Clin Neurosci. 2000;2:111–128.
   PubMedGoogle Scholar
• Doenhoff M, Coles G, Pica-Mattoccia L, et al. Chemotherapy and drug resistance in schistosomiasis, fascioliasis and tapeworm infections. In: Mayers D, editor. Antimicrobial drug resistance. New York (NY): Humana Press; 2009. p. 629–646.
   Google Scholar
• Morgan JA, Dejong RJ, Snyder SD, et al. Schistosoma mansoni and Biomphalaria: past history and future trends. Parasitol. 2001;123(Suppl):S211–228.
   PubMed Web of Science ®Google Scholar
• Cioli D, Pica-Mattoccia L. Current and future antischistosomal drugs. In: Secorand WE, Colley D, editors. Schistosomiasis, Vol. 10. New York (NY):Springer; 2005. p. 191–206.
   Google Scholar
• Panic G, Duthaler U, Speich B, et al. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014;4:185–200.
   PubMed Web of Science ®Google Scholar
• Adenowo AF, Oyinloye BE, Ogunyinka BI, et al. Impact of human schistosomiasis in sub-Saharan Africa. Brazilian J Infect Dis. 2015;19:196–205.
   PubMed Web of Science ®Google Scholar
• Bahmani M, Rafieian-Kopaei M, Hassanzadazar H, et al. A review on most important herbal and synthetic antihelmintic drugs. Asian Pacific J Trop Med. 2014;7(Suppl 1):S29–S33.
   Web of Science ®Google Scholar
• Pica-Mattoccia L, Cioli D. Sex- and stage sensitivity of Schistosoma mansoni to in vivo and in vitro praziqunantel treatment. Int J Parasitol. 2004;34(4):527–533.
   PubMed Web of Science ®Google Scholar
• Mutapi F. Changing policy and practice in the control of pediatric schistosomiasis. Pediatrics. 2015;135:536–544.
   PubMed Web of Science ®Google Scholar
• Mutapi F, Billingsley PF, Secor WE. Infection and treatment immunizations for successful parasite vaccines. Trends Parasitol. 2013;29:135–141.
   PubMed Web of Science ®Google Scholar
• King CH, Muchiri EM, Ouma JH. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis. 2000;6(6):585–595.
   PubMed Web of Science ®Google Scholar
• Massoud AM, Shalaby HA, El Khateeb RM, et al. Effects of Mirazid(®) and myrrh volatile oil on adult Fasciola gigantica under laboratory conditions. Asian Pacific J Trop Biomed. 2012;2:875–884.
   PubMedGoogle Scholar
• Botros S, William S, Ebeid F, et al. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg. 2004;71:206–210.
   PubMed Web of Science ®Google Scholar
• El Ridi RA, Tallima HA. Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res. 2013;4(5):467–478.
   PubMedGoogle Scholar
• Gelmedin V, Dissous C, Grevelding CG. Re-positioning protein-kinase inhibitors against schistosomiasis. Future Med Chem. 2015;7(6):737–752.
   PubMed Web of Science ®Google Scholar
• Huang HH, Rigouin C, Williams DL. The redox biology of schistosome parasites and applications for drug development. Curr Pharm Des. 2012;18(24):3595–3611.
   PubMed Web of Science ®Google Scholar
• El-Lakkany NM, El-Din SH, Sabra AN, et al. Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni. Mem Inst Oswaldo Cruz. 2011;106(7):814–822.
   PubMed Web of Science ®Google Scholar
• Keiser J, Silué KD, Adiossan LK, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis. 2014;8(7):e2975.
   PubMed Web of Science ®Google Scholar
• Panic G, Vargas M, Scandale I, et al. Activity profile of an FDA-approved compound library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(7):e0003962.
   PubMed Web of Science ®Google Scholar
• Russell-Stothard J, Sousa-Figueiredo JC, Betson M, et al. Schistosomiasis in African infants and preschool children: let them now be treated. Trends Parasitol. 2013;29(4):197–205.
   PubMed Web of Science ®Google Scholar
• Mutapi F, Burchmore R, Mduluza T, et al. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis. 2005;192(6):1108–1118.
   PubMed Web of Science ®Google Scholar
• Black CL, Muok EM, Mwinzi PN, et al. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis. 2010;202(3):399–405.
   PubMed Web of Science ®Google Scholar
• Magak P, Chang-Cojulun A, Kadzo H, et al. Case-control study of posttreatment regression of urinary tract morbidity among adults in Schistosoma haematobium-Endemic Communities in Kwale County, Kenya. Am J Trop Med Hyg. 2015;93(2):371–376.
   PubMed Web of Science ®Google Scholar
• Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrl Chemoth. 2014;69:863–870.
   PubMed Web of Science ®Google Scholar